Perrigo Company Plc
Could not find a ticker for this position, may be a filing error
A maker of over-the-counter self-care products, Perrigo supplies store-brand medicines to retailers and also sells its own brands like Opill®, Mederma®, Compeed®, and Solpadeine® across North America and Europe. The company traces back to 1887, when Michigan general-store owner Luther Perrigo began packaging medicines and household goods for other country stores — and pioneered the private-label idea by printing each store's own name on the labels. The company still bears his name today.
Granted 32.1K · Bought 1.0K · Sold 35.0K
Granted 171.3K · Bought 25.0K
Granted 26.9K · Bought 15.4K
Granted 99.5K · Bought 8.0K
Granted 49.3K · Bought 13.4K
Granted 26.9K
Granted 44.4K · Sold 20.8K
Granted 26.0K
Granted 34.0K
Granted 18.7K
Granted 8.8K
Granted 14.6K
Granted 7.1K · Bought 6.1K
Granted 26.0K
Granted 22.8K
Granted 28.8K
Granted 3.5K
Granted 13.2K
Granted 18.7K · Sold 17.6K
Granted 10.4K
Granted 10.6K
Granted 6.7K · Bought 1.0K
Granted 9.3K
Granted 7.0K · Bought 1.3K
Granted 8.8K · Sold 9.0K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Andersen SvendEVP & President CHCI · 8 transactions | +95.9% | 175.6Kas of Aug 2024 | 32.1K | 1.0K | 35.0K |
| Lockwood-Taylor PatrickFormer CEO and director · 23 transactions | — | 123.2K | 171.3K | 25.0K | — |
| Parker Geoffrey M.Director · 11 transactions | — | 122.8K | 26.9K | 15.4K | — |
| Bezerra Eduardo GuaritaEVP & Chief Financial Officer · 24 transactions | +2370.8% | 84.7K | 99.5K | 8.0K | — |
| Willis RobertEVP & CHRO · 30 transactions | +256.7% | 52.4K | 49.3K | 13.4K | — |
| Alford Bradley ADirector · 8 transactions | +65.9% | 45.5K | 26.9K | — | — |
| Janish Ronald CraigEVP, Gbl Ops & SC & CTO · 18 transactions | +62.3% | 40.6Kas of Jun 2025 | 44.4K | — | 20.8K |
| O'Connor DonalDirector · 6 transactions | +51.3% | 39.1K | 26.0K | — | — |
| Ashford Orlando DDirector · 6 transactions | +456.3% | 27.7K | 34.0K | — | — |
| Karaboutis AdrianaDirector · 4 transactions | +99.1% | 27.6Kas of May 2025 | 18.7K | — | — |
| Mann Erica LDirector · 2 transactions | +144.6% | 21.7Kas of May 2024 | 8.8K | — | — |
| Quinn GrainneEVP, Chief Medical Officer · 8 transactions | +49.9% | 21.1Kas of Apr 2024 | 14.6K | — | — |
| Ives AlisonEVP & Chief Scientific Officer · 14 transactions | +121.2% | 18.5Kas of Jul 2024 | 7.1K | 6.1K | — |
| Manzone AlbertDirector · 6 transactions | +198.5% | 16.4K | 26.0K | — | — |
| Brown Julia MDirector · 6 transactions | — | 15.3K | 22.8K | — | — |
| Khoury RobertoEVP and President of CSCI · 10 transactions | — | 13.1K | 28.8K | — | — |
| Hanson KyleEVP & General Counsel · 2 transactions | +14.4% | 11.1Kas of Apr 2024 | 3.5K | — | — |
| Farrington ThomasEVP and CIO · 6 transactions | +278.8% | 10.7Kas of Apr 2024 | 13.2K | — | — |
| Kindler Jeffrey BDirector · 5 transactions | -26.7% | 10.6Kas of May 2025 | 18.7K | — | 17.6K |
| Samuelson JonasDirector · 4 transactions | — | 8.9K | 10.4K | — | — |
| Ball DavidEVP & CBDO · 4 transactions | — | 7.8K | 10.6K | — | — |
| Atkinson CharlesEVP, General Counsel & Sec. · 3 transactions | — | 7.7K | 6.7K | 1.0K | — |
| Schmelter TrionaEVP & President CSCA · 6 transactions | — | 6.7Kas of Jun 2025 | 9.3K | — | — |
| Lennox AbigailEVP and CSO · 5 transactions | — | 6.6K | 7.0K | 1.3K | — |
| Doyle Katherine C.Director · 3 transactions | -5.5% | 6.0Kas of Sep 2024 | 8.8K | — | 9.0K |
| Egan Kevin FrancisDirector · 2 transactions | — | 3.8K | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -11.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.